Home › Cardiomyopathy › Washington › Seattle
Cardiomyopathy clinical trials in Seattle, WA
4 studies for Cardiomyopathy are looking for participants at sites in and around Seattle (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
TRITON-CM: A Study to Evaluate Nucresiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy
RecruitingPhase 3
- Clinical Trial Site, Seattle
Multicenter Trial of ECMO in Children With Severe Cardiac Failure Using the Cardiohelp System
RecruitingPhase 2
- Seattle Children's Hospital, Seattle
Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant
RecruitingPhase 3
- University of Washington Medical Center, Seattle
Modeling Mortality in Duchenne Muscular Dystrophy Cardiomyopathy: Identification of Surrogate Outcome Measures for DMD Drug Trials
RecruitingObservational study
- Seattle Children's, Seattle
About Cardiomyopathy
Cardiomyopathy is a disease that causes the heart to become enlarged, thick, or stiff. Read about the different types, their symptoms, and treatments.
More about Cardiomyopathy on MedlinePlus
Cardiomyopathy trials in other cities
- New York City, NY10 studies
- Boston, MA9 studies
- Washington, DC8 studies
- Rochester, MN8 studies
- Baltimore, MD7 studies
- San Diego, CA7 studies
- Charleston, SC6 studies
- Richmond, VA6 studies
- Indianapolis, IN6 studies
- Philadelphia, PA6 studies
- Dallas, TX6 studies
- St. Louis, MO6 studies
Other studies in Seattle
- Non-Small Cell Lung Cancer53 studies
- Cancer (all types)49 studies
- Prostate Cancer42 studies
- Acute Myeloid Leukemia40 studies
- Breast Cancer39 studies
- Metastatic Cancer39 studies
- Colorectal Cancer34 studies
- Lung Cancer33 studies
- Ovarian Cancer30 studies
- Multiple Myeloma22 studies
- Myelodysplastic Syndromes21 studies
- Acute Lymphoblastic Leukemia21 studies
From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.